In conclusion, this multicenter, observational study provides ‘real life’ information on the efficacy and safety of T-DM1 in patients with metastatic HER2-positive breast cancer who experienced progression on prior taxane and HER2-neu inhibition approaches. The gene discussed is ERBB2; the disease is breast carcinoma.